Alessa Therapeutics is developing localized treatments for solid organ disease.
Location: United States, California, San Carlos
Employees: 1-10
Total raised: $15M
Founded date: 2018
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.12.2024 | Seed | $15M | - |
Mentions in press and media 9
| Date | Title | Description |
| 01.07.2026 | Alessa Therapeutics Receives Positive FDA Feedback Following Type C Meeting on Enolen’s Pivotal Phase 3 Trial Design | FDA Confirms Single Study with Primary Endpoint of Progression-Free Survival Sufficient for NDA; company expects to begin pivotal Phase 3 trial in mid-2027 Our productive discussions with the FDA have established a clearly defined and achie... |
| 29.05.2026 | Alessa Therapeutics Announces Enolen Phase 1 Study Presentation Receives 'Best Poster' Award at the American Urological Association Annual Meeting | SAN CARLOS, CA, UNITED STATES, May 29, 2026 /EINPresswire.com/ -- Alessa Therapeutics (“Alessa”), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology for the treatment of early-stage prostate cancer... |
| 22.05.2026 | Alessa Therapeutics Appoints Dr. Peter Carroll and Dr. Neal Shore to Lead Clinical Advisory Board | Internationally Renowned Prostate Cancer Researchers to Support Continued Clinical Advancement of Enolen Dr. Carroll and Dr. Shore are recognized luminaries in the field of urologic oncology research, each with a wealth of experience in the... |
| 07.01.2026 | Alessa Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Cam Gallagher, President and CEO, and Pamela Munster, MD, Founder and Chief Scientific Advisor, will present a company overview and clinical update SAN CARLOS, CA, UNITED STATES, January 7, 2026 /EINPresswire.com/ -- Alessa Therapeutics (“A... |
| 09.01.2025 | Alessa Therapeutics Announces First Patient Enrolled in Enolen Study for Localized Drug Delivery for Prostate Cancer | SAN CARLOS, CA, UNITED STATES, January 9, 2025 /EINPresswire.com/ -- Alessa Therapeutics, Inc., a privately held drug development company developing an innovative and proprietary localized drug delivery technology for the treatment of prost... |
| 19.12.2024 | Alessa Therapeutics: Drug Delivery Technology Company Raises $15 Million (Seed) | Alessa Therapeutics – a clinical-stage drug development company pioneering an innovative and proprietary localized drug delivery technology for the early interception of cancer and other diseases – announced the closing of a $15 million see... |
| 13.12.2024 | Alessa Therapeutics Closes $15M Seed Financing | Alessa Therapeutics, a San Carlos, CA-based clinical-stage drug development company, raised $15M in Seed funding. The round was led by Mission BioCapital, with participation from Johnson & Johnson. The company intends to use the funds t... |
| 12.12.2024 | Alessa Therapeutics Announces Closing $15M Seed Financing | Alessa is well positioned to advance our pipeline and leverage our platform of tissue-targeted drug delivery for the treatment of prostate cancer and other solid organ diseases.” — Pamela Munster, M.D., Founder & Chief Executive Officer... |
| - | Alessa Therapeutics | “We drive innovation in oncology and solid organ disease through development of advanced treatment and early interception.” |